Skip Navigation
  Search Menu
Find an Expert


Evan Jacob Lipson, M.D.

Photo of Dr. Evan Jacob Lipson, M.D.

Associate Professor of Oncology


Expertise: Clinical Trials, Immunotherapy, Medical Oncology, Melanoma

Research Interests: Melanoma; Immunotherapy

Request an Appointment

I live in Maryland

Request an appointment through MyChart!

I live outside of Maryland

Request Appointment

I live outside of the United States

Request Appointment


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-616-7660

401 N. Broadway
Weinberg Building
Baltimore, MD 21231 map
Phone: 410-955-8893
Fax: 410-955-8587

Sibley Memorial Hospital
Appointment Phone: 202-660-6500

5255 Loughboro Road, NW
1st Floor
Washington, DC 20016 map
Fax: 202-660-6501


Evan J. Lipson, M.D., is a medical oncologist at the Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, as well as an assistant professor of oncology at Johns Hopkins University School of Medicine. Dr. Lipson established the Johns Hopkins Melanoma Program at Sibley in 2012 and opened the program's first clinical trial in the Washington, D.C. region in 2015. He is board certified in internal medicine and medical oncology. 

Dr. Lipson has an expertise in melanoma and treatment of patients with cutaneous malignancies, specifically regarding the use of novel immunotherapies. 

Dr. Lipson earned his undergraduate degree from the University of Maryland and his medical degree from Mount Sinai School of Medicine. He completed a residency in internal medicine at Johns Hopkins University School of Medicine, as well as a fellowship in medical oncology. 

Dr. Lipson is the founder of, a non-profit organization that chronicles the stories of cancer patients who find interesting and meaningful ways to add life to their days. He is a member of The Johns Hopkins Hospital Multidisciplinary Cancer Committee, as well as the American Society for Clinical Oncology (ASCO), the Society for Melanoma Research, the Society for Immunotherapy of Cancer and the Eastern Cooperative Oncology Group. 

Dr. Lipson is a nationally-recognized educator and lecturer about the clinical use of cancer immunotherapy, specifically regarding the management of immune-mediated drug toxicities, often in organ transplant recipients.

Dr. Lipson has contributed to numerous clinical trials, publications and presentations. His research focuses on investigating new therapies for patients with various stages of melanoma, ranging from preventing disease recurrence in high-risk patients to developing innovative drug therapies for patients with advanced disease. Dr. Lipson works to optimize combinations of immune-based therapies, such as cancer vaccines and immune checkpoint inhibitors, in order to achieve maximal anti-tumor activity. As a part of the Johns Hopkins Melanoma and Cancer Immunotherapy programs, Dr. Lipson also collaborates with basic and translational scientists in order to investigate biomarkers of drug efficacy. He is a peer reviewer for The Journal of the National Comprehensive Cancer Network, the ASCO Educational Book Expert Panel, the Journal for Immunotherapy of Cancer, Cancer Management and Research, Cancer Discovery, and Clinical Cancer Research. more


  • Associate Professor of Oncology

Departments / Divisions

  • Medicine at Sibley Memorial Hospital
  • Oncology - Medical Oncology



  • MD, Mount Sinai School of Medicine (2005)


  • Johns Hopkins University School of Medicine / Medicine (2008)


  • Johns Hopkins University School of Medicine / Oncology (2011)

Board Certifications

  • American Board of Internal Medicine / Internal Medicine (2008)
  • American Board of Internal Medicine / Medical Oncology (2010)

Research & Publications

Clinical Trials

View Dr. Lipson's current research trials at Sibley Memorial Hospital here.

Selected Publications

View all on Pubmed

Kaunitz GJ, Loss M, Rizvi H, Ravi S, Cuda JD, Bleich KB, Esandrio J, Sander I, Le DT, Diaz LA Jr, Brahmer JR, Drake CG, Hollmann TJ, Lacouture ME, Hellmann MD, Lipson EJ, Taube JM. "Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern." Am J Surg Pathol. 2017 Oct;41(10):1381-1389.

Kaunitz GJ, Cottrell TR, Lilo M, Muthappan V, Esandrio J, Berry S, Xu H, Ogurtsova A, Anders RA, Fischer AH, Kraft S, Gerstenblith MR, Thompson CL, Honda K, Cuda JD, Eberhart CG, Handa JT, Lipson EJ, Taube JM. "Melanoma subtypes demonstrate distinct PD-L1 expression profiles." Lab Invest. 2017 Sep;97(9):1063-1071. doi: 10.1038/labinvest.2017.64. Epub 2017 Jul 24.

Naidoo J, Cappelli LC, Forde PM, Marrone KA, Lipson EJ, Hammers HJ, Sharfman WH, Le DT, Baer AN, Shah AA, Albayda J, Manno RL, Haque U, Gutierrez AK, Bingham CO 3rd, Brahmer JR. "Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade." Oncologist. 2017 Jun;22(6):627-630. doi: 10.1634/theoncologist.2016-0390. Epub 2017 Jun 2. No abstract available.

Sunshine JC, Nguyen PL, Kaunitz GJ, Cottrell TR, Berry S, Esandrio J, Xu H, Ogurtsova A, Bleich KB, Cornish TC, Lipson EJ, Anders RA, Taube JM. "PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison." Clin Cancer Res. 2017 Aug 15;23(16):4938-4944. doi: 10.1158/1078-0432.CCR-16-1821. Epub 2017 Apr 20.

Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL. "Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma." J Nucl Med. 2017 Sep;58(9):1421-1428. doi: 10.2967/jnumed.116.188839. Epub 2017 Mar 30.

Activities & Honors


  • Seize The Days


  • Johns Hopkins Multidisciplinary Cancer Committee


  • American Society for Clinical Oncology


  • Society for Melanoma Research


  • Society for Immunotherapy of Cancer


  • Eastern Cooperative Oncology Group


Videos & Media

Recent News Articles and Media Coverage

How Does Immunotherapy Work?, Melanoma Research Alliance, Feb. 2, 2016

In The Beginning, Hopkins Medicine, Fall 2014

Keytrude Just One of a New Class of Cancer Drugs to Restart the Immune System, Healthline News, Sept. 10, 2014

New Skin Cancer Drug Approved, CNN, Jan. 31, 2012

'Seize the Days' Project Documents a Life with Cancer, WAMU 88.5, Jan. 6, 2012

Giving Patients a Way to Share Their Stories, Cancer.Net, April 4, 2011

Is this you? Edit Profile